4Tallman MS. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology Am Soc Hematol Educ Program,2005,143-150.
5Kantarjian H, O'brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer, 2006,106: 1090-1098.
6Saito K, Nakamura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combination withgranulocyte colony-stimulating factor (CAG regimen)for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML,secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol, 2000, 71:238-244.
7Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic eytogeneties on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 Trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood,1998,92: 2322-2333.
8Miller AB, Hooqstraten MB, Staquet M, et al. Reporting results of cancer treatment. Cancer,1981,47 :207-214.
9Hofmann WK, Heil G, Zander C, et al. Intensive chemotherapy with idarubicin, cytarabine, etoposide,and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol, 2004, 83:498-503.
10Lang K, Earle CC, Foster T, et al, Trends in the treatment of acute myeloid leukemia in the elderly. Drug Aging, 2005,22:943-955.
